CING (Cingulate) GF Score: 35/100 (As of Jun. 27, 2026) — 59% Above Median


CING Cingulate Inc CING
35 GF Score
Price $4.94
! 1 Warning Sign
View Full Analysis

What is Cingulate GF Score?

Cingulate CING +4.20% 35 GF Score is 35 as of Jun. 27, 2026, which is 59% above its 10-year median of 22.00. GuruFocus rates CING with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Cingulate has the GF Score of 35, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 2/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Cingulate might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Cingulate  (NAS:CING) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Cingulate GF Score Related Terms

CING vs TIL, XLO, GOSS: GF Score Comparison

For the Biotechnology subindustry, Cingulate's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cingulate GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's GF Score distribution charts can be found below:

* The bar in red indicates where Cingulate's GF Score falls into.


CING
35GF Score
Cingulate Inc CING
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 35 mean?
Cingulate (CING) has a GF Score of 35 as of Jun. 27, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Cingulate and its competitors. This is 59% above median its historical median of 22.00. Over the past decade, Cingulate's GF Score has ranged from 16.00 to 43.00.
Is Cingulate's GF Score too high?
Cingulate's current GF Score of 35 is 59% above median its 10-year median of 22.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 43.00. Overall, Cingulate has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's GF Score compare to TIL and XLO?
Cingulate's GF Score of 35 can be compared against companies in the Biotechnology industry. Historically, Cingulate's own GF Score has ranged from 16.00 to 43.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Cingulate and its competitors. Cingulate's current GF Score is 35, which is 59% above median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current GF Score of 35. The current GF Score is 35, which is 59% above median its 10-year median of 22.00. Cingulate's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Cingulate (CING), the current GF Score is 35 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
35GF Score

Get the complete analysis for CING

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.94
Price